Cardiovascular Disease and Depression: Bidirectional Mechanisms, Shared Inflammation, Treatment Safety, and Clinical Outcomes

Cardiovascular disease (CVD) and major depressive disorder (MDD) are individually among the leading causes of disability worldwide. Their co-occurrence is far more common than chance alone would predict, and their interaction is profoundly synergistic — each worsening the prognosis of the other through overlapping biological, behavioral, and psychosocial mechanisms. The World Health Organization projects that by 2030, both ischemic heart disease and unipolar depression will rank among the top three contributors to global disease burden, making their intersection one of the most consequential comorbidities in modern medicine.

Depression following acute myocardial infarction (MI) was recognized as clinically significant as early as the 1970s, but it was the landmark work of Frasure-Smith and colleagues in the 1990s that established post-MI depression as an independent predictor of cardiac mortality. Since then, research has moved well beyond the unidirectional model — depression as a reaction to cardiac illness — toward a sophisticated understanding of bidirectional causality. Depression is now recognized not only as a consequence of CVD but as a robust, independent risk factor for its development, with effect sizes comparable to traditional cardiovascular risk factors such as hyperlipidemia and smoking.

This article examines the epidemiology, shared neurobiological mechanisms, diagnostic challenges, treatment safety and efficacy, and prognostic implications of CVD-depression comorbidity. The clinical stakes are enormous: patients with comorbid depression and CVD have 2- to 3-fold higher mortality rates compared to those with CVD alone, and depression remains undertreated in cardiac populations despite compelling evidence that identification and management can improve both psychiatric and cardiovascular outcomes.

The prevalence of clinically significant depression among patients with established CVD is approximately 20–30%, roughly 2–3 times the rate observed in the general population. Among patients hospitalized for acute coronary syndromes (ACS), studies consistently report point prevalence rates of 15–20% for major depressive disorder and up to 40% when subsyndromal depressive symptoms are included, as assessed by instruments such as the Beck Depression Inventory (BDI ≥10) or the Patient Health Questionnaire-9 (PHQ-9 ≥10).

Importantly, the relationship is bidirectional. In initially healthy cohorts, depression increases the risk of incident coronary heart disease by approximately 80% (relative risk ~1.8), as established by multiple meta-analyses. A 2014 meta-analysis by Gan and colleagues, pooling data from over 300,000 participants across 30 prospective cohort studies, reported a pooled relative risk of 1.30 (95% CI: 1.22–1.40) for incident CVD associated with depression, with the risk being particularly elevated for MI (RR ~1.30) and coronary death. The Interheart study, a large case-control study across 52 countries, identified psychosocial factors including depression as one of the nine modifiable risk factors for MI, with a population-attributable risk of approximately 33%.

Conversely, incident depression rates following MI are substantial. The ENRICHD (Enhancing Recovery in Coronary Heart Disease) trial screened over 9,000 post-MI patients and found that approximately 20% met criteria for major depression, while another 27% had significant depressive symptoms. Longitudinal data from the Heart and Soul Study demonstrated that depressive symptoms at baseline predicted a 50% greater rate of cardiovascular events over a mean 4.8-year follow-up, with much of this risk mediated by behavioral factors — particularly physical inactivity.

Sex differences are notable: women with CVD have approximately 1.5–2 times higher rates of comorbid depression than men with CVD. Age effects are also relevant — younger MI patients (<55 years) have paradoxically higher depression rates than older patients, and depression in younger post-MI cohorts carries an especially poor cardiac prognosis.

The biological underpinnings of CVD-depression comorbidity involve multiple overlapping pathophysiological systems. These are not merely correlative associations but represent mechanistic pathways through which each condition actively promotes the other.

1. Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

Chronic HPA axis hyperactivation is one of the most consistently documented biological abnormalities in major depression. Elevated cortisol levels — particularly the loss of normal diurnal cortisol rhythm and impaired dexamethasone suppression — are found in approximately 40–60% of patients with melancholic or severe depression. Hypercortisolemia exerts direct cardiovascular harm through multiple mechanisms: promotion of visceral adiposity, insulin resistance, endothelial dysfunction, hypertension, and a procoagulant state. Cortisol promotes the expression of adhesion molecules on vascular endothelium, accelerates atherosclerotic plaque formation, and impairs nitric oxide-mediated vasodilation. The net effect is that chronic depression creates a sustained neuroendocrine milieu that mirrors metabolic syndrome — a well-established cardiovascular risk state.

2. Autonomic Nervous System Imbalance

Depression is associated with a characteristic pattern of sympathetic hyperactivation coupled with parasympathetic (vagal) withdrawal. This manifests as reduced heart rate variability (HRV), elevated resting heart rate, and impaired baroreflex sensitivity — all of which are independent predictors of cardiac mortality. Reduced HRV, typically measured as decreased SDNN (standard deviation of normal-to-normal R-R intervals) or reduced high-frequency power on spectral analysis, has been consistently documented in depressed post-MI patients. In the landmark studies by Carney and colleagues, depressed post-MI patients exhibited significantly lower 24-hour HRV compared to non-depressed post-MI controls, and this autonomic dysfunction partially mediated the association between depression and cardiac mortality. Sympathetic overdrive increases myocardial oxygen demand, promotes arrhythmogenesis, and contributes to coronary vasoconstriction.

3. Systemic Inflammation and the Cytokine Hypothesis

Perhaps the most intensively researched shared mechanism is systemic low-grade inflammation. Both depression and atherosclerotic CVD are characterized by elevated pro-inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α). Meta-analyses have confirmed that depressed individuals show mean elevations of CRP approximately 1.4–2.0 times higher than non-depressed controls, and IL-6 levels approximately 1.5–1.8 times higher.

These cytokines are not passive bystanders. They actively participate in the pathogenesis of both conditions through a process sometimes termed the cytokine hypothesis of depression. Pro-inflammatory cytokines cross the blood-brain barrier and activate central inflammatory signaling via microglial activation. Within the brain, inflammation shifts tryptophan metabolism away from serotonin synthesis and toward the kynurenine pathway, generating neurotoxic metabolites such as quinolinic acid (a glutamate receptor agonist) while depleting neuroprotective metabolites such as kynurenic acid. This results in both serotonergic deficiency and glutamatergic excitotoxicity — two core neurochemical features of depression.

Simultaneously, the same inflammatory milieu promotes endothelial dysfunction, oxidized LDL uptake by macrophages, foam cell formation, plaque instability, and thrombotic risk in the vasculature. The CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) provided critical proof-of-concept that targeting inflammation with IL-1β inhibition (canakinumab) reduced recurrent cardiovascular events in patients with elevated CRP, independent of lipid lowering — supporting inflammation as a causal cardiovascular pathway rather than an epiphenomenon.

4. Platelet Hyperreactivity and Thrombotic Risk

Depressed patients demonstrate enhanced platelet activation, including increased expression of platelet surface glycoprotein IIb/IIIa, elevated plasma levels of platelet factor 4 and β-thromboglobulin, and heightened platelet aggregation in response to serotonin and collagen. Serotonin plays a dual role: it is a central neurotransmitter involved in mood regulation and a peripheral mediator of platelet aggregation. Platelets store serotonin and release it upon activation, amplifying the thrombotic cascade. This creates a mechanistic link between serotonergic dysfunction in depression and increased thrombotic risk in CVD. SSRIs, notably, normalize platelet hyperreactivity — a mechanism that may partly explain their observed cardiovascular benefits beyond mood improvement.

5. Genetic and Epigenetic Overlap

Genome-wide association studies (GWAS) have identified shared genetic loci between depression and coronary artery disease. Polymorphisms in the serotonin transporter gene (SLC6A4), particularly the short (s) allele of the 5-HTTLPR polymorphism, have been associated with both increased depression vulnerability and enhanced platelet reactivity. The BDNF Val66Met polymorphism, which reduces activity-dependent secretion of brain-derived neurotrophic factor, is associated with depression risk and has been implicated in impaired vascular repair mechanisms. More recently, Mendelian randomization studies suggest that genetic liability to depression has a causal effect on coronary artery disease risk, even after accounting for behavioral mediators.

Diagnosing major depressive disorder in patients with CVD presents substantial clinical challenges. The symptom overlap between depression, cardiac disease, and their respective treatments creates a diagnostic landscape rife with false positives, missed diagnoses, and attributional biases.

Somatic Symptom Overlap

DSM-5-TR diagnostic criteria for MDD include several symptoms that are common in cardiac illness independent of depression: fatigue, sleep disturbance, psychomotor retardation, appetite changes, and diminished concentration. A patient recovering from MI or heart failure may present with all of these symptoms on purely cardiac or deconditioning-related grounds. Two diagnostic approaches have been studied: the inclusive approach (count all symptoms regardless of potential medical explanation) and the exclusive/substitutive approach (replace somatic symptoms with cognitive-affective alternatives). Research, including work from the ENRICHD trial investigators, suggests that the inclusive approach performs better in terms of sensitivity and predictive validity for cardiac outcomes, as somatic symptoms of depression carry prognostic significance regardless of their presumed etiology.

Screening Instruments

The PHQ-9 and PHQ-2 are the most widely validated screening tools in cardiac populations. The American Heart Association (AHA) issued a Science Advisory in 2008 recommending routine depression screening in all cardiac patients using the PHQ-2 as an initial screen, followed by the full PHQ-9 for those screening positive. A PHQ-9 cutoff of ≥10 has sensitivity of approximately 80–85% and specificity of approximately 80–90% for major depression in cardiac populations. The BDI-II is also commonly used in research settings. Importantly, screening alone is insufficient — positive screens must be followed by clinical diagnostic evaluation.

Differential Diagnosis Considerations

Several conditions must be distinguished from primary MDD in the cardiac setting:

• Adjustment disorder with depressed mood: Common after acute cardiac events; typically less severe and self-limited, resolving within 6 months.
• Demoralization: A syndrome of existential distress and helplessness that overlaps with but is distinct from MDD; patients may retain hedonic capacity despite pervasive hopelessness.
• Medication-induced depression: Beta-blockers have historically been implicated, though a 2021 meta-analysis by Riemer and colleagues found no significant association between beta-blocker use and depression incidence (RR 1.02, 95% CI: 0.96–1.08), largely debunking this long-held clinical belief. However, centrally-acting antihypertensives (e.g., reserpine, methyldopa) and some antiarrhythmics can contribute to depressive symptoms.
• Hypothyroidism: Common in cardiac patients (especially post-amiodarone use), causing fatigue, cognitive slowing, and mood changes that mimic depression.
• Heart failure-related cognitive impairment: Cerebral hypoperfusion in advanced heart failure can produce apathy, executive dysfunction, and psychomotor slowing resembling depression.

The Problem of Under-Recognition

Despite guideline recommendations, depression remains substantially underdiagnosed in cardiac settings. Studies suggest that cardiologists identify depression in only 25–35% of cases that meet formal criteria. Contributing factors include time constraints, normalization of distress ("of course they're depressed — they just had a heart attack"), lack of psychiatric training, and uncertainty about treatment responsibilities. This under-recognition has direct consequences: untreated depression predicts worse medication adherence, lower cardiac rehabilitation participation, and higher healthcare utilization.

The treatment of depression in cardiac patients requires careful consideration of both psychiatric efficacy and cardiovascular safety. The evidence base, while imperfect, provides clear guidance on several key questions.

SSRIs: First-Line Agents with Established Cardiac Safety

Selective serotonin reuptake inhibitors are the best-studied antidepressants in CVD populations and are considered first-line treatment based on their established cardiac safety profile. Three landmark trials form the foundation of this evidence:

The SADHART Trial (Sertraline Antidepressant Heart Attack Randomized Trial, 2002): This pivotal RCT randomized 369 patients with MDD following ACS to sertraline (50–200 mg/day) versus placebo for 24 weeks. Sertraline demonstrated no adverse cardiovascular effects — no differences in left ventricular ejection fraction, ventricular arrhythmias, QTc prolongation, or cardiovascular mortality. Regarding efficacy, sertraline showed a modest overall advantage over placebo (CGI-I response: 67% vs. 53%), with stronger separation in the subgroup with recurrent depression (prior episodes before ACS), where response rates significantly favored sertraline. The overall antidepressant effect was modest — consistent with the moderate effect sizes observed in general depression trials.

The ENRICHD Trial (2003): This large trial (N=2,481) tested cognitive behavioral therapy (CBT) versus usual care in depressed post-MI patients. Notably, patients who failed to respond to CBT received open-label sertraline. While the primary endpoint (recurrent MI or death) was not significantly different between groups, a secondary analysis found that patients who received SSRIs had a 43% reduction in death or recurrent MI compared to those who did not (HR 0.57, 95% CI: 0.38–0.86). Although this finding must be interpreted cautiously as it derives from a non-randomized comparison, it has been influential in clinical practice.

The CREATE Trial (Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy, 2007): This 2×2 factorial RCT in depressed coronary artery disease patients compared citalopram versus placebo and interpersonal psychotherapy (IPT) versus clinical management. Citalopram was significantly superior to placebo (HAM-D mean difference: −3.3 points, p=0.005), while IPT added no benefit over clinical management. This trial provided the clearest evidence of SSRI antidepressant efficacy in a cardiac population.

Across these trials, SSRI response rates (≥50% symptom reduction) in CVD populations are approximately 50–65%, with remission rates around 30–40% — modestly lower than rates observed in general depression populations, suggesting that cardiac comorbidity may confer some degree of treatment resistance. The number needed to treat (NNT) for SSRIs versus placebo for depression response in cardiac patients is approximately 7–10.

Other Antidepressants: Safety Considerations

Mirtazapine: Limited cardiac safety data. The small MIND-IT substudy (Myocardial Infarction and Depression-Intervention Trial) found mirtazapine was well-tolerated post-MI but did not demonstrate superiority over placebo for depression. Weight gain and metabolic effects are concerns in patients already at cardiovascular risk.

SNRIs (venlafaxine, desvenlafaxine, duloxetine): These agents carry a dose-dependent risk of sustained hypertension (approximately 5–13% at higher doses for venlafaxine), making them second-line in hypertensive or heart failure patients. QTc effects are generally minimal but should be monitored.

Tricyclic antidepressants (TCAs): These are contraindicated or strongly discouraged in CVD populations. TCAs produce Type IA antiarrhythmic effects (sodium channel blockade), can prolong QTc, impair cardiac conduction, cause orthostatic hypotension, and are lethal in overdose. The Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that Type I antiarrhythmic agents increased mortality in post-MI patients — a finding with direct implications for TCA safety in this population.

Bupropion: Generally considered safe from a cardiac standpoint, though it can cause dose-dependent hypertension. Its dopaminergic/noradrenergic mechanism may offer advantages for patients with prominent fatigue or anhedonia. Limited dedicated cardiac safety trial data.

Psychotherapy is an important component of depression treatment in CVD, both as monotherapy for mild-to-moderate depression and as an adjunct to pharmacotherapy in more severe presentations.

Cognitive Behavioral Therapy (CBT)

CBT is the most extensively studied psychotherapy in cardiac-depression comorbidity. The ENRICHD trial found that CBT produced a statistically significant but clinically modest improvement in depression compared to usual care (BDI change: −9.1 vs. −5.8 at 6 months, p<0.001). The clinical significance was debated because the magnitude of improvement was small and the intervention did not reduce the primary cardiovascular endpoint. However, ENRICHD's CBT protocol was relatively brief (average of 11 sessions) and was delivered by therapists with variable expertise in cardiac populations, potentially diluting its effect. Subsequent smaller trials have reported more robust depression outcomes with CBT adapted for cardiac patients.

Exercise-Based Interventions

Physical exercise has a strong evidence base for both depression and CVD, making it a uniquely dual-acting intervention. The UPBEAT study (Understanding Prognostic Benefits of Exercise and Antidepressant Therapy) by Blumenthal and colleagues demonstrated that aerobic exercise (three 45-minute sessions per week at 70–85% heart rate reserve for 16 weeks) was comparable in antidepressant efficacy to sertraline in patients with coronary heart disease and MDD. Depression remission rates were approximately 40% for exercise versus 36% for sertraline (not significantly different). Moreover, exercise improved HRV and reduced inflammatory markers — addressing underlying pathophysiological mechanisms.

Cardiac rehabilitation programs, which incorporate structured exercise with education and psychosocial support, reduce all-cause mortality by approximately 20–25% and have been shown to significantly reduce depressive symptoms. Unfortunately, depressed cardiac patients are significantly less likely to enroll in and complete cardiac rehabilitation — a paradox in which those most likely to benefit are least likely to participate.

Collaborative Care Models

The Bypassing the Blues trial (2009) demonstrated that a telephone-delivered collaborative care intervention for post-CABG (coronary artery bypass graft) depression — involving a care manager, structured depression monitoring, and stepped pharmacotherapy — achieved significantly greater depression improvement than usual care over 8 months. The CODIACS (Comparison of Depression Interventions after Acute Coronary Syndrome) vanguard trial similarly supported the feasibility and efficacy of centralized, stepped collaborative care for post-ACS depression. These models, which integrate depression management within cardiac care systems, show particular promise because they address the fragmentation between cardiology and psychiatric care that characterizes current practice.

This is arguably the most critical — and most frustrating — question in the field. The answer is nuanced: treating depression clearly improves quality of life, functional status, and depression outcomes, but its impact on hard cardiac endpoints (MI, cardiovascular mortality) remains uncertain.

Evidence from Randomized Trials

Neither SADHART nor ENRICHD demonstrated a significant reduction in cardiovascular events or mortality from depression treatment. However, both trials were statistically underpowered for cardiac endpoints. SADHART enrolled only 369 patients and had a 24-week follow-up — far too few events to detect meaningful differences in cardiovascular outcomes. ENRICHD, despite its larger sample, achieved only modest depression improvement, making it difficult to test the hypothesis that effective depression treatment improves cardiac outcomes.

The most informative data come from observational analyses and secondary endpoints:

• The ENRICHD SSRI analysis (mentioned above) showed a 43% relative risk reduction in death or recurrent MI among SSRI users, though this was not randomized.
• A meta-analysis by Pizzi and colleagues (2011) pooling data from depression treatment trials in post-ACS patients found no significant effect on cardiac mortality (RR 0.83, 95% CI: 0.60–1.15) but a trend toward benefit that might reach significance with larger samples.
• Registry and cohort data consistently show that persistent or treatment-resistant depression post-ACS carries the worst cardiac prognosis, while patients who respond to depression treatment have outcomes approaching those of non-depressed cardiac patients.

The "Dose-Response" Hypothesis

An emerging perspective suggests that the key predictor of cardiac outcome is not whether depression treatment was offered but whether depression actually remitted. Data from ENRICHD and other trials suggest that patients who remain depressed despite treatment have the worst cardiovascular outcomes, while those who achieve remission — regardless of the treatment modality — have significantly better prognosis. This has led to the concept that depression should be treated to target (remission) rather than simply treated, paralleling treat-to-target approaches for LDL cholesterol and blood pressure.

Several clinical features predict both worse psychiatric outcomes and worse cardiovascular outcomes in patients with comorbid CVD and depression:

Predictors of Poor Outcome

• History of recurrent depression preceding the cardiac event: Patients with depression that antedated their MI or ACS have worse treatment response and higher cardiac event rates compared to those experiencing a first depressive episode post-MI. In SADHART, recurrent depression showed both greater severity and better SSRI-placebo separation, but it also carries a fundamentally worse prognosis.
• Severity of depression: More severe depression (e.g., BDI >25 or PHQ-9 >20) is associated with proportionally higher cardiovascular risk and lower remission rates with standard treatments.
• Somatic-affective depression symptom profile: Factor-analytic studies distinguish somatic-affective depression symptoms (fatigue, appetite/sleep disturbance, psychomotor changes) from cognitive-affective symptoms (sadness, guilt, worthlessness). The somatic-affective cluster more strongly predicts cardiac events and mortality, possibly because it reflects the inflammatory and autonomic pathways linking depression to CVD. The Symptom Checklist work by de Jonge and colleagues from the ENRICHD data established this distinction.
• Low heart rate variability at baseline: Patients with both depression and low HRV represent a particularly high-risk subgroup. Carney et al. demonstrated that depressed post-MI patients with SDNN <70 ms have substantially elevated mortality risk.
• Elevated inflammatory markers: High baseline CRP (>3 mg/L) and IL-6 levels predict both treatment-resistant depression and adverse cardiovascular events, suggesting that the inflammatory subtype of depression may be a distinct, harder-to-treat entity.
• Low social support and social isolation: ENRICHD identified low perceived social support as an independent predictor of post-MI mortality, and depression combined with social isolation is particularly lethal.
• Non-adherence to cardiac medications: Depression reduces adherence to statins, aspirin, beta-blockers, and antiplatelet agents by approximately 2-fold (pooled OR ~2.0 per meta-analysis by Gehi et al.), creating a behavioral pathway through which depression worsens cardiac outcomes.

Predictors of Better Outcome

• First episode of depression occurring after the cardiac event (new-onset post-MI depression)
• Strong social support networks
• Engagement in cardiac rehabilitation
• Early response to antidepressant treatment (within 4–6 weeks)
• Higher physical functional capacity at baseline

Heart failure (HF) deserves special mention because depression prevalence is even higher in HF than in coronary artery disease, and the pathophysiological interactions are especially intense. Meta-analyses estimate depression prevalence at approximately 21–22% for clinician-rated MDD in HF populations and up to 38–42% when self-report questionnaires are used (reflecting substantial subsyndromal depression). Among patients with advanced HF (NYHA Class III–IV), rates approach 40–50%.

The pathophysiology of HF-depression comorbidity involves neurohormonal activation (renin-angiotensin-aldosterone system and sympathetic nervous system overdrive), cerebral hypoperfusion, chronic systemic inflammation, and the psychosocial burden of functional impairment, dyspnea, and repeated hospitalizations. Depression in HF independently predicts hospital readmission — a critical quality metric — with depressed HF patients showing 30-day readmission rates approximately 1.5–2 times higher than non-depressed HF patients.

Treatment evidence in HF is more limited than in post-ACS depression. The MOOD-HF trial (2016) — the largest RCT of antidepressant treatment in HF — randomized 372 patients with HF and MDD to escitalopram versus placebo for 24 months. The trial found no significant difference in depression outcomes (primary endpoint: change in depression severity on MADRS) or cardiac outcomes. This negative result was surprising and has been debated: escitalopram doses were relatively modest, and the trial may have been affected by high placebo response rates. The SADHART-CHF trial (sertraline in HF) was similarly negative for both depression and cardiac endpoints. These findings suggest that SSRIs may be less effective for depression in HF specifically, possibly because the neurobiological drivers of depression in HF (cerebral hypoperfusion, neurohormonal activation) are partially distinct from those in post-ACS depression.

Several active areas of investigation may reshape the management of CVD-depression comorbidity in the coming years:

Anti-Inflammatory Interventions

Given the centrality of inflammation in both conditions, direct anti-inflammatory strategies are being explored. The CANTOS trial demonstrated that canakinumab (anti-IL-1β) reduced cardiovascular events, and exploratory analyses suggested improvements in fatigue and well-being, though formal depression outcomes were not assessed. The Cardiovascular Inflammation Reduction Trial (CIRT) tested low-dose methotrexate in stable coronary disease but was halted early for futility — perhaps because methotrexate targets a different inflammatory pathway (not IL-1β/IL-6/CRP). Ongoing research is evaluating whether anti-inflammatory agents that successfully reduce CRP and IL-6 also improve depression in cardiac populations.

Precision Medicine and Biomarker-Guided Treatment

The heterogeneity of both depression and CVD suggests that identifying biological subtypes could improve treatment matching. The "inflamed depression" phenotype — characterized by elevated CRP, anhedonia, fatigue, and psychomotor slowing — may respond preferentially to anti-inflammatory augmentation strategies. Conversely, the "anxious-depressive" phenotype with prominent autonomic dysregulation might benefit most from vagal nerve stimulation or HRV biofeedback. Clinical trials parsing depression subtypes in cardiac populations are underway.

Gut Microbiome

Emerging evidence links gut dysbiosis to both depression and CVD through the production of trimethylamine N-oxide (TMAO) — a gut microbiome-derived metabolite associated with atherosclerotic cardiovascular events — and through modulation of systemic inflammation and the gut-brain axis. While this research is early-stage, it points toward potential shared therapeutic targets.

Digital Health and Remote Monitoring

Digital mental health interventions — app-based CBT, telepsychiatry, and remote symptom monitoring — may address the access barriers that prevent depressed cardiac patients from receiving mental health care. The COVID-19 pandemic accelerated adoption of telehealth in both cardiology and psychiatry, and preliminary data suggest that digitally delivered collaborative care models can be effective for post-ACS depression.

Cardiac Safety of Novel Antidepressants

Newer agents including esketamine/ketamine (with potential acute hemodynamic effects including transient hypertension), psilocybin (with uncertain cardiovascular effects at the 5-HT2B receptor), and brexanolone/zuranolone (GABA-A modulators with limited cardiac data) require dedicated cardiac safety evaluation before they can be confidently used in CVD populations. The need for cardio-psychiatric safety data for emerging antidepressants represents a significant gap in the current evidence base.

The evidence reviewed above supports several concrete clinical recommendations:

• Screen all cardiac patients for depression using validated instruments (PHQ-2/PHQ-9), per the AHA Science Advisory, at initial presentation, during hospitalization, and at follow-up visits. Screening should be linked to a clear diagnostic and treatment pathway — screening without follow-up is ineffective.
• SSRIs (sertraline, citalopram, escitalopram) are first-line pharmacotherapy for moderate-to-severe depression in CVD, with established cardiac safety. Avoid TCAs. Use SNRIs with caution in hypertensive patients. Monitor QTc with citalopram/escitalopram, particularly in patients on other QT-prolonging medications.
• Prescribe structured exercise and strongly encourage cardiac rehabilitation enrollment, as exercise addresses both depression and cardiovascular risk through multiple mechanisms.
• Treat depression to remission target, not merely to response. Persistent depression, even if improved, continues to carry cardiovascular risk. Step up treatment (dose optimization, switching, augmentation, or adding psychotherapy) if remission is not achieved within 8–12 weeks.
• Implement collaborative care models that integrate depression management within cardiology practice, using care managers, measurement-based care, and psychiatric consultation — an approach with the strongest evidence for closing the treatment gap.
• Address behavioral mediators explicitly: medication adherence, physical activity, smoking cessation, and cardiac rehabilitation participation. These behavioral pathways account for a substantial proportion of the depression-CVD outcome link and are modifiable.
• Monitor long-term: Depression in CVD is frequently recurrent. Continue antidepressant treatment for at least 6–12 months after remission, consistent with general depression treatment guidelines, and monitor for relapse at subsequent cardiac visits.